Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · Real-Time Price · USD
13.33
0.00 (0.00%)
Feb 21, 2025, 4:00 PM EST - Market closed
Dynavax Technologies Revenue
In the year 2024, Dynavax Technologies had annual revenue of $277.25M with 19.36% growth. Dynavax Technologies had revenue of $72.03M in the quarter ending December 31, 2024, with 29.56% growth.
Revenue (ttm)
$277.25M
Revenue Growth
+19.36%
P/S Ratio
6.25
Revenue / Employee
$679,525
Employees
408
Market Cap
1.65B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 277.25M | 44.96M | 19.36% |
Dec 31, 2023 | 232.28M | -490.40M | -67.86% |
Dec 31, 2022 | 722.68M | 283.24M | 64.45% |
Dec 31, 2021 | 439.44M | 399.19M | 991.75% |
Dec 31, 2020 | 40.25M | 5.03M | 14.29% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
DVAX News
- 1 day ago - Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance - PRNewsWire
- 2 days ago - Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy - PRNewsWire
- 3 days ago - Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting - Business Wire
- 3 days ago - Exclusive: Investor Deep Track launches proxy fight at Dynavax, nominates 4 directors - Reuters
- 11 days ago - Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty - Benzinga
- 15 days ago - Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025 - PRNewsWire
- 26 days ago - Dynavax Advances Board Refreshment Program - PRNewsWire